Stocks of the Hour: Telix Pharmaceuticals, AVITA Medical, EZZ Life Science
Stocks of the Hour: Telix Pharmaceuticals, AVITA Medical, EZZ Life Science
To register for today's webinar click here.
要註冊今天的網絡研討會，請單擊此處。
Telix Pharmaceuticals (ASX:TLX) announces additional positive data from the ProstACT SELECT trial of TLX591. TLX591 is an investigational anti-PSMA1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Shares are trading 7.81 per cent higher at $16.97.
Telix Pharmicals（澳大利亞證券交易所股票代碼：TLX）宣佈了來自 TLX591 Prostact SELECT 試驗的更多陽性數據。TLX591 是一種正在研發的抗PSMA1放射性抗體藥物偶聯物（RadC）療法，用於治療mcRPC，其區別在於短短的兩週給藥方案。股價上漲7.81％，至16.97美元。
AVITA Medical (ASX:AVH) announces FDA approval of RECELL GO. The RECELL GO System is a cell harvesting device that harnesses the regenerative properties of a patient's own skin to treat thermal burn wounds and full-thickness skin defects. Shares are trading 12.78 per cent higher at $3.00.
AVITA Medical（澳大利亞證券交易所股票代碼：AVH）宣佈美國食品藥品管理局批准RECELL GO。RECELL GO 系統是一種細胞收集設備，它利用患者自身皮膚的再生特性來治療熱燒傷口和全層皮膚缺陷。股價上漲12.78％，至3.00美元。
EZZ Life Science (ASX:EZZ) has signed a five-year sales agreement with Pinehills (Hong Kong). Pinehills has committed to purchasing EZZ-branded products with a minimum value of A$15m in the first 12-months. Shares are trading 3.06 per cent higher at $1.01.
EZZ Life Science（澳大利亞證券交易所股票代碼：EZZ）已與Pinehills（香港）簽署了爲期五年的銷售協議。Pinehills已承諾在最初的12個月內購買最低價值爲1500萬澳元的EZZ品牌產品。股價上漲3.06％，至1.01美元。
